• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel pleuromutilin gylcoside derivatives are useful agents with activity against gram-positive and gram-negative bacteria anaerobes and mycoplasma.
    公开号:SU902666A3
    申请号:SU782696955
    申请日:1978-12-07
    公开日:1982-01-30
    发明作者:Нагарайан Рамакришнан
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR OBTAINING PLHIBROMUTILIN GLYCOSITIC DERIVATIVES
    I
    This invention relates to a process for the preparation of new pleuromutilin derivatives with valuable pharmacological properties.
    The purpose of the invention is to obtain new compounds expanding the arsenal of means of influencing a living organism.
    The goal is achieved by synthesis based on the known. Noah. reaction 10, glycosidic derivatives of General formula
    O-C-CH -R
    .2.
    where R is a group of formula 5 5
    rV
    6
    where R is (Cj-Cc) alkanoyl; R is OR, where R is as defined above, or MR R, where R and R are independently H or (Cd-C3) alkyl; ,, H or group CHj OR; R - OR or a group of the formula
    SNGOK
    权利要求:
    Claims (2)
    [1]
    where it has the above values, provided that R is not | 5 the domonomer of D-xylopyrano3 V, which is the reciprocal action of a glycosyl of formula HR, where R has the above values, with illevutriline of formula O CH Cli CH, in the presence of potassium carbonate in ace top. The target product is known methods. The preferred embodiment of the process is the addition of a solution of iodoplevromutilin in acetone to a solution of the per-0-acylmercaptosucara derivative. The potassium carbonate is added to the mixture while mixing and stirring is continued. The reaction mixture is extracted with methylene chloride. The extraction solvent is removed by evaporation. Example i. Preparation of 4-deoxy 14- (2,3,4,6-tetra-0-acetyl-P-D-glucopyranosyl) thioacetoxy mutilin. A solution of iodopromovomylin in the amount of 577.3 kg in acetone (2 ml) is added to a solution consisting of 2,3,4,6-tetra-O-acetyl-ji- D - glitch pyranosyl mercaptan (428.8 mg ) in 2 ml of acetone. A solution of KjCOj in the amount of 168.4 mg in 1 ml of water was added to the stirred reaction mixture, and the resulting solution was subjected to stirring at room temperature for 30 minutes. The resulting reaction mixture was then poured into deionized water (25 ml) and the aqueous solution was extracted with methylene chloride. The resulting extract is dried with anhydrous sodium sulfate, filtered and evaporated under vacuum until a dry product is obtained. The residue is dried in deep akume for 1.5 hours, receiving 989.7 mg of 14 - deoxy-1, 4,6 - tetra-0-acetyl-p-D glucopyronyl) thioacetoxy mutaline, M 724. NMR: 4 CHg at 0.7 (d) 088 (d), 1.17 (c1, 1.94 LC). Example 2. A. Obtaining hydrobromide 2,3,4-tri-O-acetyl-1-thiuronium- | 3 - 0-xylopyranose. 2,3,4-Three-O-acetyl-oC-D-xylopyranosyl bromide in an amount of 1.3 g (mmol), dissolved in 3 ml of acetone. Thiourea is added to this solution in an amount of 33Q mg (4.33 mmol). After adding additional acetone (about 3 ml), the resulting solution is heated at reflux (in an oil bath at 70 ° C for about 20 minutes). The product is crystallized by cooling the reaction mixture in an ice bath. The crystals are separated by filtration, washed with a minimum amount of acetone and prepared to give 849 mg of hydrobromide, 2,3,4-tri-O-acetyl-1-thiuronium-P-0-xylopyranose; m.p. 174175 C.V. Preparation of 2,3,4-tri-O-acetyl-1-thio-O-xylopyranose. Water (5 ml) and carbon tetrachloride (5 ml) were added to 2,3,4-tri-O-acetyl-I-thiuronium-) hydrobromide 3-0-xylopyranose in the amount of 608.4 mg (1.486 mmol) obtained at stage A, and 218 mg (1.14 mmol) of NSjiSj O. The reaction mixture is heated at reflux for 40 minutes and then cooled to room temperature. The carbon tetrachloride layer is separated. The aqueous layer is washed twice with 10 millimeter portions of carbon tetrachloride. The fractions were combined, dried over anhydrous sodium sulphate, filtered and evaporated under vacuum. To obtain 212.9 mg of 2,3,4-tri-O-acetyl-1-thio-O-xylopyranose as a yellow oil. This product is further purified on a silica gel column, to give 332.3 mg of an oil which crystallizes; m.p. 117-122C. C. Preparation of .14-deoxy-14-C C 2,3, 4 -tri-O-acetyl-O-xylopyranosyl) thioacetoxy 1 utilin. The "2,3,4-tri-O-acetyl-1-thio-β-P-xylopyranose in 1.46 g (5 mmol) obtained in step B is dissolved in 10 ml of acetone. A solution of 2.48 g is added (5.08 mmol) of iodo plevromutilin in 10 ml of acetone. To the stirred reaction mixture was added rastOD 721 mg (5.19 mmol) in 5 ml of water. The resulting solution was stirred at room temperature for 20 minutes and then poured into deionized water (100 ml). This solution is extracted with methylene chloride. The resulting solution is dried with anhydrous sodium sulfate, filtered, evaporated to dryness under vacuum, and then dried under high vacuum for 8 hours to obtain 3.8 g of product as a white foam, which is crystallized from either a mixture of diethyl ether and hexane or diethyl ether and ethyl acetate. m.p. 91-97 ° C. Mass spectrum; . NMR: 4 CHj at 0.74 Cd), 0.89 (d), 1.18 (s), 1.96 (. S), Example 3. Preparation of 14-deoxy-14- (2, 3,4- three-0-acetyl- | - D-arabinopyranosyl) thioacetoxy mutilin. 2,3,4-Three-O-acetyl-1-thio-D-apabinose in the amount of 3.177 g (0.0109 MOLB), prepared as described in Example 2 (stages A and b), dissolved in 20 ml of acetone, and 5.31 g (0.0109 mol) of iodoplromoutilin, also dissolved in acetone (20 ml), are mixed together. 1.506 g, l / ff, 0109 mol) KjCOj in 10 ml of water is added. The resulting solution was stirred at room temperature for 30 minutes and then drunk into water (100 ml). The aqueous solution was extracted three times with 50 ml of methylene chloride. The extracts are combined, dried with anhydrous sodium sulfate, and filtered; the filtrate is evaporated under vacuum to obtain a crude product in an amount of 7.1 g. This product is purified by high-performance liquid chromatography, elution is performed using a mixture consisting of toluene and ethyl acetate in a ratio of 1: 1; the treating system is supplied at a rate of 250 ml / min; collected fractions have a volume of 250 ml. The fraction content is determined by thin layer chromatography on silica gel using mixtures of toluene and ethyl acetate (1: 1) as a solvent, and iodine as a solvent. Fractions 17-22 contain the maximum amount of purified product. These fractions with the formation of 4.989 g of 14-deoxy-Ji4 are combined and evaporated under vacuum - 2, 3,4-tri-0-acetyl - (- - arabinopyranyl) thioacetoxy mutilin. Г 653; NMR: 4 CH at 0.74 Ca), 0.89 eg), 1, i6 Cc), 1.46 Cc). Yield 70%. Example 4. Preparation of 14-deoxy-14- (2,3,4-tri-0-acetyl--1 arabinopyra-1-fsyl thioacetoxy mutilin. 4,636 g (0.0095 mol) of iodopromo mutilin is reacted with 2,3,4-three -0-acetyl-1-1-thio-L-apaOH-nose in the amount of 2.76 g (0.0095 mol in accordance with the procedure described in example 3, to obtain 6.265 g of the crude product, which is purified by chromatography high resolution, as described in example 3, using a gradient solvent from 4 liters of toluene to 4 liters of a mixture consisting of ethyl acetate and toluene in a 1: 1 ratio. T. As a result, 3.53 g of 14-deoxy-C2,3,4-tri-0-aceto-p-L-arabinopyranosyl) thioacetoxy mutilin. M 652. NMR: 4 CH 3 at 0.72 (d), 0, 92 (o), 1.17 (, s), 1.45 (s). Yield 54%. Example 5. Preparation of 14-deoxy-14- (2,3,4,6-tetra-O-acetyl- - O-galactopyranosyl) thioacetoxyT mutinin 9.27 g (o, 019 mol) iodoplevromoutilin is reacted with 2,3,4, 6-tetra-O-acetyl-j5 - D hapaktopyranosyl mercaptan in the amount of 6.96 g (05019 mol according to the procedure described in Example 1, 14.14 g of unrefined product was obtained. This product is purified by high-performance liquid chromatography as described in Example 3 using a Gradient solvent from 4 L toluene to 4 L a mixture of toluo and ethyl acetate in a 1: 1 ratio of 1) using thin layer chromatography. 3.99 g of 14-deoxy-14 (2, 3,4,6-tetra-0-acetyl-0-galactoranosyl) thioacetoxy mutilin are obtained. NMR: 0.74 (9), 0.89 (d), 1, 17 (s), 1.45 (s). Yield 29%. Example 6. 14-Deoxy-14- (.2, 3,4-tri-0-acetyl-6-1-xylopyrano-thyl-acetoxy-mutilin was prepared according to the procedure of Example 2, but L xylose is used as the initial I I material. In the final stage, 31 g of iodine. P-promutyline is reacted with 2.1, 4 tri-0-acetyl-1-thio-p-D-xylose in an amount of 9 g, to obtain 39.6 g of the crude product. This product was purified by high resolution liquid chromatography as described in measure 3, but using a gradient no solvent (8 l) from toluene to mixture toluene and ethyl acetate (7: 3). The purified fractions are crystallized from a mixture of toluene-ethyl acetate, to obtain 21.05 g of and-deoxy-14 - (, 2,3,4-tri-0-acetyl-p-L-silico-pyrroline thioacea; mutilen; mp 210-213 C; + 653. NMR: 4 CHj at 0.73 (d) 0.88 (d), 1.77 (s), 1.46 LC). Yield, 49%. Example 7 Preparation of 14-deoxy-14- (2-deoxy-2 (M, M-dimethylamino-3,4, 6-tri-0-acetyl- / 3-p-glucopyranosyl) - thioacetoxy 1 mutiline. To a solution of 10.8 g ( 0.05 mol of C-glucosamine hydrochloride in 250 ml of water was added 250 ml of a 37% aqueous formaldehyde solution and 5 g (10%) of palladium on carbon. The resulting mixture is hydrogenated until the theoretical absorption is not achieved for conversion to 2-deoxy-2 (N, M-dimethylamino) -0-glucosamine. The catalyst was removed by filtration and the filtrate was lyophilized. The product obtained is acetylated with acetic anhydride and pyridine to obtain the corresponding tetra-0-acetyl derivative. This substance is converted into 2-deoxy-2- (M, N-dimethylamino) -3,4,6-3-0-acetyl-D-glucopyranosylbromide, which is further translated into The corresponding 1-mercapto derivative in accordance with the procedure described in the example.
    [2]
    2. Interaction of 2-deoxy-2- (N, N-dimethylamino) -3,4,6-tri-Oacetyl-1-thio-) -glucopyranose with iodo pleromo utilin. in accordance with the method described in example 2 (stage C) gives the target product; M 728. NMR: 4 CHj at 0.70 (d), 0.85 (d), 1.14 (s), 1.83 (s); CH (CH.j at 0.91 (d). Example 8. Preparation of 14-deoxy-14- (4-0- (2,3,4,6-tetra-O-acetyl-1-D-glucopyranosyl) - 2,3,6-tri-Oacetyl-D-0-glucopyranosypine mutilin thioacetoxy3 This compound is obtained in the procedure described in accordance with Example 2, except that maltose oxa-0-acetate is used as a starting material. 6 g of iodo plevromutilin are reacted with 4-0- (2,3,4,6-tetra-0-acetyl-o (E-glucopyranosyl) -2,3, 6-tri-O-acetyl-1-thiol- -0- glucopyranose in the amount of 11.8 g, obtained in accordance with the procedure described in Example 2, to obtain 17 g of pro white foam. This product is further purified by high resolution liquid chromatography using 8 liters of a gradient solvent from ethyl acetate to a mixture of ethyl acetate and ethanol (l: I) to give 1.12 g of product. M 1012. NMR: 4 СН at 0.74 (g), 0.90 (g), 1.20 (s), t 1.46 (s). Yield 6%. New pleuromutilin glycoeid derivatives are valuable drugs against gram-positive and gram-negative bacteria, anaerobic bacteria and mycoplasmas. The proposed pleuromutilin glycosides are relatively non-toxic compounds; for example, the 50% lethal dose (LDso) for 14-deoxy-14- (p-P-xylopyranosyl) thioacetoxy} mutilin and 14-deoxy-1. (.P-xylopyranosyl) thioacetoxy -19,20- dihydromoutiline when injected into the peritoneum of mice is more than 1500 mg / kg of live weight, and a 50% lethal dose (LDjo) for 14-deoxy-14-- {3,4,6-three-0-acetyl-2-deoxy -2- (hydroxyimino) -P-glucopyranosyl) hydroxyacetoxy-19,20-dihydromutilin, also when injected into the peritoneum of mice, is more than 300 mg / kg of live weight. / The claims The method of obtaining pleuromutilin glycosidic derivatives, the general formula I is 90266 9 tons, e R is a group of the formula rV - (Cj, -C) alkanoyl; is the OR group, where R is the above or. - NR R ;, er R and R are independently represented by eboy H or (CL-C) alkyl; CH, 0 #; hydrogen or an OR group or a group of formula L in the case of. accepted for op - has the above mean of 1970, provided that R is not 1. 6 jj-anomer-0 of xylopyrinosyl, characterized in that. glycosyl of formula HR, where R has the above values, is subjected to interaction with iodopleuromutilin of the general formula, loss of potassium carbonate in the information sources, taken into account in the examination of Fizer L., Fizer M. Reagents of ganic synthesis. M., Mir s. 187.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU902666A3|1982-01-30|Method of preparing pleuromutiline glycoside derivatives
    Miyashita et al.1977|Pyridinium p-toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranylation of alcohols
    Kraus et al.1988|A direct synthesis of C-glycosyl compounds
    US3822254A|1974-07-02|Synthesis of 25-hydroxycholesterol
    FUJITA et al.1981|Antitumor activity of acylated oridonin
    Suhara et al.1972|Total synthesis of kasugamycin
    DE2750812C2|1986-01-09|4-alkoxy-4-desmethoxydaunomycins and process for their preparation
    Probst et al.1981|19‐O‐Acetylchaetoglobosin B and 19‐O‐Acetylchaetoglobosin D, Two New Metabolites of Chaetomium globosum
    JPH07116209B2|1995-12-13|Sialosyl ceramides and method for producing the same
    Carmely et al.1986|Neviotine-A, a new triterpene from the Red Sea sponge Siphonochalina siphonella
    US5463142A|1995-10-31|Method for the preparation of D-chiro-inositol
    Haskell et al.1977|Synthesis ov deoxy sugar. Deoxygenation of an alcohol utilizing a facile nucleophilic displacement step
    SU910118A3|1982-02-28|Process for producing n -glucofuranozid-6-yl-n -nitrosocarbamide
    SU797583A3|1981-01-15|Method of preparing anthracycline-glycosides
    Sasaki et al.1979|Synthesis of adamantane derivatives. 47. Photochemical synthesis of 4-azahomoadamant-4-enes and further studies on their reactivity in some cycloadditions
    US4448724A|1984-05-15|Synthesis of 4-demethoxydaunomycinone
    US4764605A|1988-08-16|Process for selectively deacetylating acetyl derivatives of saccharides
    US4496485A|1985-01-29|Asymmetric 7-O-|-4-demethoxydaunomycinones
    MATSUURA et al.1978|Studies on the constituents of useful plants. VI. Constituents of the calyx of Diospyros kaki |, and carbon-13 nuclear magnetic resonance spectra of flavonol glycosides
    Suami et al.1973|Aminocyclitols. XXIX. Synthesis of Inosadiamines via 1, 3-Biimino-1, 3-dideoxy-inositols
    Nakatani et al.1968|Synthetic Studies on Rotenoids Part I. A Novel Synthesis of |-Munduserone
    Cardona et al.1973|Syntheses of the. beta.-D-glucosides of 4-and 5-hydroxy-1-naphthyl N-methylcarbamate
    CH642973A5|1984-05-15|ANTITUMORANTHRACYCLINE WITH BRANCHED CHAIN AMINODEOXY SUGAR REMAINS.
    ZELINSKI et al.1958|Racemic 2-Hydroxymethyl-2, 3-dihydro-4H-pyran, a Model Carbohydrate1
    Wild et al.1995|Synthesis of sphingosines, 11. Convenient synthesis of phytosphingosine and sphinganine from D‐galactal and D‐arabitol
    同族专利:
    公开号 | 公开日
    EP0002588B1|1983-04-06|
    CH639103A5|1983-10-31|
    IT1160316B|1987-03-11|
    GR72774B|1983-12-05|
    CS219342B2|1983-03-25|
    RO84425A|1984-06-21|
    FR2411205B1|1981-08-14|
    US4130709A|1978-12-19|
    IT7830657D0|1978-12-06|
    DD139858A5|1980-01-23|
    DK539578A|1979-07-05|
    ES475854A1|1980-05-16|
    FR2411205A1|1979-07-06|
    PL211492A1|1979-11-19|
    JPS5498751A|1979-08-03|
    EP0002588A1|1979-06-27|
    ATA871578A|1980-09-15|
    IL56115A|1984-01-31|
    AT362065B|1981-04-27|
    RO84426B|1984-08-30|
    IE782421L|1979-06-08|
    BE872489A|1979-06-05|
    RO80082A|1983-02-01|
    LU80619A1|1979-06-05|
    DE2862226D1|1983-05-11|
    CA1109866A|1981-09-29|
    GB2009738B|1982-11-10|
    GB2009738A|1979-06-20|
    RO80082B|1983-01-30|
    HU181429B|1983-07-28|
    RO84426A|1984-06-21|
    IE47533B1|1984-04-18|
    PL123850B1|1982-12-31|
    ZA786872B|1980-08-27|
    YU281878A|1983-06-30|
    PT68857A|1979-01-01|
    CS219344B2|1983-03-25|
    FI783709A|1979-06-09|
    AU524665B2|1982-09-30|
    IL56115D0|1979-03-12|
    AU4216278A|1979-06-14|
    RO84425B|1984-08-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5594359A|1979-01-12|1980-07-17|Sandoz Ag|Novel pleuromutilin derivativestheir manufacture and use|
    US5041534A|1983-03-22|1991-08-20|Merrell Dow Pharmaceuticals|Process for preparing antibiotic L 17054|
    FR2551442B1|1983-09-05|1987-04-30|Centre Nat Rech Scient|NEW FURANIC DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION|
    US5077398A|1986-11-18|1991-12-31|Merck & Co., Inc.|Process for isolation of avermectin B1 components with improved purity and subsequent isolaton of B2 components|
    US5843908A|1990-09-28|1998-12-01|Bristol-Myers Squibb Company|Pradimicins l and fl, and derivatives thereof|
    US5696096A|1990-09-28|1997-12-09|Bristol-Myers Squibb Company|Pradimicin derivatives|
    AT400674B|1991-07-24|1996-02-26|Biochemie Gmbh|PHARMACEUTICAL PLEUROMUTILIN PREPARATION|
    JP3816570B2|1996-02-16|2006-08-30|塩水港精糖株式会社|Acylating agent|
    GB9614017D0|1996-07-04|1996-09-04|Biochemie Gmbh|Organic compounds|
    UY25225A1|1997-10-29|2000-12-29|Smithkline Beecham Plc|PLEUROMUTILINE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS|
    GB0218578D0|2002-08-09|2002-09-18|Glaxo Group Ltd|Novel method|
    GB0308114D0|2003-04-08|2003-05-14|Glaxo Group Ltd|Novel compounds|
    US7875630B2|2003-09-03|2011-01-25|Glaxo Group Limited|Process salts compositions and use|
    US6838576B1|2003-10-23|2005-01-04|3M Innovative Properties Company|Process for preparing functional group-containing olefinic compounds|
    US8268791B2|2004-08-25|2012-09-18|Aegis Therapeutics, Llc.|Alkylglycoside compositions for drug administration|
    US8440631B2|2008-12-22|2013-05-14|Aegis Therapeutics, Llc|Compositions for drug administration|
    US9895444B2|2004-08-25|2018-02-20|Aegis Therapeutics, Llc|Compositions for drug administration|
    US20060046962A1|2004-08-25|2006-03-02|Aegis Therapeutics Llc|Absorption enhancers for drug administration|
    US20140162965A1|2004-08-25|2014-06-12|Aegis Therapeutics, Inc.|Compositions for oral drug administration|
    GB0513058D0|2005-06-27|2005-08-03|Sandoz Ag|Organic compounds|
    US8173594B2|2006-06-23|2012-05-08|Aegis Therapeutics, Llc|Stabilizing alkylglycoside compositions and methods thereof|
    US7998927B2|2006-06-23|2011-08-16|Aegis Therapeutics, Llc|Stabilizing alkylglycoside compositions and methods thereof|
    US8084022B2|2006-06-23|2011-12-27|Aegis Therapeutics, Llc|Stabilizing alkylglycoside compositions and methods thereof|
    US8226949B2|2006-06-23|2012-07-24|Aegis Therapeutics Llc|Stabilizing alkylglycoside compositions and methods thereof|
    US20090326193A1|2006-06-23|2009-12-31|Aegis Therapeutics Llc|Stabilizing alkylglycoside compositions and methods thereof|
    EP1972618A1|2007-03-20|2008-09-24|Nabriva Therapeutics AG|Pleuromutilin derivatives for the treatment of diseases mediated by microbes|
    JP5613657B2|2008-03-28|2014-10-29|ヘイル バイオファーマ ベンチャーズ，エルエルシー|Administration of benzodiazepine composition|
    WO2016044846A1|2014-09-19|2016-03-24|Emory University|Saccharide analogs and agents for the diagnosis and therapy of bacterial infections|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/858,507|US4130709A|1977-12-08|1977-12-08|Pleuromutilin glycoside derivatives|
    [返回顶部]